LakeShore Biopharma (LSB) director Xue Linnan files initial Form 3

Rhea-AI Filing Summary

LakeShore Biopharma Co., Ltd. director Xue Linnan has filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing establishes their status as a director and formally begins periodic ownership reporting, but does not itself reflect any buy or sell transaction.

Key Terms

Form 3, beneficial ownership, reporting person

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"initial statement of beneficial ownership for company insiders"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

reporting person regulatory

"reportingPersons: [{"name": "Xue Linnan""

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Xue Linnan

(Last) (First) (Middle)

C/O BUILDING NO. 2

38 YONGDA ROAD, DAXING DISTRICT

(Street)

BEIJING DAXING DISTRICT 102629

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
LakeShore Biopharma Co., Ltd. [ LSB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Linnan Xue	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does LakeShore Biopharma (LSB) director Xue Linnan’s Form 3 mean?

It means Xue Linnan has officially become a reporting insider of LakeShore Biopharma. Form 3 is an initial statement of beneficial ownership that begins ongoing disclosure of future insider holdings and transactions.

Did Xue Linnan buy or sell LakeShore Biopharma (LSB) shares in this Form 3?

No buy or sell transactions are shown in this Form 3 data. The filing simply identifies Xue Linnan as a director and initial reporting person, without listing any specific trades in the provided information.

What is the purpose of a Form 3 for LakeShore Biopharma (LSB) insiders?

Form 3 serves as an insider’s initial beneficial ownership report when they first become an officer, director, or large shareholder. It creates a baseline for later Forms 4 and 5 that disclose ongoing trades and ownership changes.

What insider role does Xue Linnan hold at LakeShore Biopharma (LSB)?

The data identifies Xue Linnan as a director of LakeShore Biopharma Co., Ltd. Being a director makes them a reporting person under SEC rules, requiring ownership and transaction disclosures on forms such as Form 3 and Form 4.

Does this LakeShore Biopharma (LSB) Form 3 show any derivative securities?

The derivative section in the provided data is empty, indicating no listed options or similar derivative securities for this insider in this particular Form 3 snapshot. Future filings could disclose derivatives if they are later granted or held.